Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $22.00 Price Target at Wedbush

Key Points

• Wedbush lowered its price target on Ultragenyx from $25 to $22 and maintained a neutral rating; the target implies about 30% upside from the prior close.
• Ultragenyx’s quarterly revenue rose 8.2% year over year to $173 million, but missed consensus, as did its $1.16-per-share loss. Analysts’ average rating is Hold, with an average price target of $33.60.
• The company reaffirmed its 2026 revenue and 2027 profitability outlook, and expects to sell two Priority Review Vouchers for a combined $413 million.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its price target lowered by analysts at Wedbush from $25.00 to $22.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a "neutral" rating on the biopharmaceutical company's stock. Wedbush's price objective would indicate a potential upside of 30.09% from the stock's previous close.

Other analysts also recently issued research reports about the stock. Guggenheim lowered their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 4th. JPMorgan Chase & Co. downgraded Ultragenyx Pharmaceutical from an "overweight" rating to a "neutral" rating and reduced their price target for the company from $80.00 to $36.00 in a report on Thursday, September 3rd. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Barclays boosted their price target on Ultragenyx Pharmaceutical from $32.00 to $35.00 and gave the stock an "overweight" rating in a research report on Monday, September 21st. Finally, Morgan Stanley upped their price objective on shares of Ultragenyx Pharmaceutical from $18.00 to $20.00 and gave the stock an "equal weight" rating in a report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $33.60.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE opened at $16.91 on Wednesday. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -2.87 and a beta of 0.37. Ultragenyx Pharmaceutical has a one year low of $12.73 and a one year high of $39.89. The company's 50-day simple moving average is $16.64 and its two-hundred day simple moving average is $22.81.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by ($0.06). The company had revenue of $173.00 million for the quarter, compared to the consensus estimate of $182.49 million. The firm's quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.81) EPS. Equities analysts expect that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $15.27, for a total transaction of $107,897.82. Following the transaction, the chief financial officer directly owned 89,229 shares in the company, valued at approximately $1,362,526.83. The trade was a 7.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 8,510 shares of company stock valued at $127,561 in the last ninety days. Company insiders own 5.20% of the company's stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc lifted its holdings in Ultragenyx Pharmaceutical by 662.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 1,001 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $48,000. Harbor Investment Advisory LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth $52,000. Parallel Advisors LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 1,440 shares during the period. Finally, Leonteq Securities AG boosted its holdings in Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 1,333 shares during the period. Hedge funds and other institutional investors own 97.67% of the company's stock.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reaffirmed its 2026 revenue and 2027 profitability guidance. It expects expense and workforce reductions to cut 2027 R&D spending by at least 50% compared with 2025. Ultragenyx third-quarter results and outlook
• Positive Sentiment: The company said it has agreements to sell two Priority Review Vouchers for a combined $413 million, providing a substantial source of cash. FDA approvals of GENGLYCOS and FAYUVI were also announced during the quarter. Ultragenyx third-quarter results and outlook
• Neutral Sentiment: Revenue rose 8.2% year over year to $173 million, including $109 million from CRYSVITA and $30 million from DOJOLVI. The quarterly loss narrowed to $1.16 per share from $1.81 a year earlier. Ultragenyx third-quarter earnings results
• Negative Sentiment: Despite year-over-year improvement, the $1.16 per-share loss was slightly wider than analysts’ roughly $1.10–$1.15 expected loss, and revenue of $173 million fell short of the $182.5 million consensus estimate. Ultragenyx Q3 loss and revenue results

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx's commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.